https://www.live-feeds.com/feed/novo-nordisk-lifts-guidance-as-rollout-of-wegovy-weight-loss-pill-continuesContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novo-nordisk-lifts-guidance-as-rollout-of-wegovy-weight-loss-pill-continueshttps://www.live-feeds.com/feed/novo-nordisk-lifts-guidance-as-rollout-of-wegovy-weight-loss-pill-continues#u188820Mon, 09 Nov 2026 19:44:43 +0000Novo Nordisk raised its 2026 outlook after reporting that Wegovy pill sales surged and outperformed expectations, with the medication reaching over 5 million prescriptions. The company cited improved demand for obesity and diabetes drugs, particularly outside the United States, as key drivers of the guidance increase.Why it mattersThe Wegovy pill, a GLP-1 weight-loss medication, has intensified competition with Eli Lilly's Zepbound and Foundayo, especially as Medicare's GLP-1 Bridge pilot program caps monthly costs at $50 for eligible seniors. Novo Nordisk's CEO stated the Wegov